MD, MSc(Hons), PGDip (Obes), MAcadTM, SCOPE (Cert.), PhDc
University of Warwick Medical School - University Hospitals Coventry and Warwickshire NHS Trust
Senior Clinical Fellow in Endocrinology, Diabetes and Metabolism - Subspecialist in Reproductive Endocrinology and Metabolic Diseases
Warwick, West Midlands | United Kingdom
Specialties: Subspecialist in Reproductive Endocrinology and Metabolic Medicine
Primary Affiliation: University of Warwick Medical School - University Hospitals Coventry and Warwickshire NHS Trust - Warwick, West Midlands , United Kingdom
PubMed Central Citations
Warwick Medical School
National and Kapodistrian University of Athens
Warwickshire Institute for the Study of Diabetes
Imperial College London
University Hospitals Coventry and Warwickshire NHS Trust
Metaxa Cancer Hospital
Warwick Medical School
University Hospitals of Coventry and Warwickshire NHS Trust
22PubMed Central Citations
Magn Reson Imaging 2018 Sep 26;51:61-68. Epub 2018 Apr 26.
University of Warwick, Clinical Sciences Research Laboratories, Clifford Bridge Road, Coventry CV2 2DX, UK; Department of Radiology, University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry CV2 2DX, UK.
Eur J Clin Invest 2018 Jul 13;48(7):e12961. Epub 2018 Jun 13.
Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Nutr Cancer 2018 Jul 21;70(5):748-754. Epub 2018 May 21.
a The ARDEN NET Centre, European Neuroendocrine Tumour Society (ENETS) Centre of Excellence (CoE), University Hospitals Coventry and Warwickshire NHS Trust , Coventry , UK.
Endocrine 2018 Apr 2;60(1):175-184. Epub 2018 Feb 2.
Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, Clifford Bridge Road, Coventry, CV2 2DX, UK.
Oncotarget 2018 Mar 30;9(24):16678-16690. Epub 2018 Mar 30.
Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK.
Oncotarget 2017 Sep 16;8(44):76961-76973. Epub 2017 Aug 16.
Division of Translational Medicine, Clinical Sciences Research Laboratories, Warwick Medical School, University of Warwick, University Hospital, Coventry, U.K.
Am J Med 2017 Jun 2;130(6):e261-e263. Epub 2017 Feb 2.
Department of Endocrinology, Diabetes and Metabolism, WISDEM Centre, UHCW NHS Trust, Coventry, United Kingdom; Centre for Reproductive Medicine, UHCW NHS Trust, Coventry, United Kingdom; Division of Translational and Experimental Medicine, University of Warwick Medical School, Coventry, United Kingdom.
Lancet Diabetes Endocrinol 2017 04 23;5(4):240-241. Epub 2017 Feb 23.
Academic Division of Diabetes, Endocrinology and Metabolism, Imperial College London, Hammersmith Campus, London, UK. Electronic address:
Anticancer Drugs 2017 02;28(2):237-241
Department of Medicine, Division of Medical Oncology & Hematopoietic Cell Transplant Program, 'Metaxa' Cancer Hospital, Piraeus, Greece.
Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 2017 Feb 16.
Low or high grade malignant neoplasms present syndromes secondary to symptoms related to local mass effects to surrounding structures or through the development of metastases. A significant number of neoplasms, irrespective of their endocrine differentiation, can present with clinical syndromes produced from the secretion of bioactive substances from tumoural cells, although this is more prevalent in neuroendocrine tumours. Occasionally syndromes related to the immune cross-reactivity of tumoural antigens with the normal tissues may also develop. These syndromes are named endocrine paraneoplastic when the specific secretory components (hormones, peptides or cytokines) are unrelated to the anticipated tissue or organ of origin. Endocrine paraneoplastic syndromes can precede, occur concomitantly or present at a later stage of tumour development and may complicate the patient’s clinical course, response to treatment, and impact overall prognosis. Their detection can facilitate the diagnosis of the underlying neoplasia, monitor response to treatment, detect early recurrences and correlate with prognosis. Although when associated with tumours of low malignant potential they usually do not affect long-term outcome, in cases of highly malignant tumours, endocrine paraneoplastic syndromes are usually associated with poorer survival outcomes. Currently, no specific underlying pathogenic mechanism has been identified although a number of plausible hypotheses have been put forward. However, advances in the localization and treatment of these syndromes have evolved and aim at early identification particularly as the number of these syndromes is expected to rise. The development of well-designed prospective multicentre trials remains a priority in the field in order to fully characterise these syndromes and provide evidence-based diagnostic and therapeutic protocols. For extended coverage of this and related topics, please see our FREE on-line web- text www.endotext.org.
Clin Endocrinol (Oxf) 2017 Jan 11;86(1):1-6. Epub 2016 Oct 11.
Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, University Hospitals of Coventry and Warwickshire NHS Trust, Coventry, United Kingdom.
Expert Review of Endocrinology & Metabolism
Introduction: Obesity prevalence remains at epidemic levels globally and is showing no signs of abating in either adult or child populations. Areas covered: Obesity-associated metabolic and reproductive diseases appear to be sexually dimorphic. Polycystic Ovary Syndrome (PCOS) and male obesity-associated secondary (hypogonadotrophic) hypogonadism (MOSH) represent two of the most common obesity associated endocrinopathies with sex-specific metabo-reproductive aberrations. These two diseases have entirely separate pathogeneses, with characteristic sex-specific clinico-pathological findings. These differences result from effects of sex-specific hormones, including estrogens and androgens. Such differences in sex-hormones also influence patterns of body-fat distribution. Expert commentary: This article focuses on sex-specific obesity-related metabolic and reproductive dysfunction. To illustrate key sex-related differences in the mechanisms by which obesity contributes towards metabolic and reproductive dysfunction, two common obesity-related conditions affecting women and men are considered: respectively, Polycystic Ovary Syndrome (PCOS) and Male Obesity-associated Secondary Hypogonadism (MOSH). KEYWORDS: Obesity, sex differences, MOSH, PCOS, estrogens, androgens, adipose tissue
Endocrinology 2016 05 18;157(5):1881-94. Epub 2016 Mar 18.
Department of Translational and Experimental Medicine (J.H., B.K.T., G.K.D., G.T., V.P., M.K., J.C., H.S.R.), Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom; Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (I.K., B.K.T., G.K.D., H.S.R.) and Arden Tissue Bank (S.J.), Department of Pathology, University Hospitals Coventry and Warwickshire National Health Service Trust, Coventry CV2 2DX, United Kingdom; Birmingham Heartlands and Solihull Hospitals (B.K.T.), Heart of England National Health Service Foundation, National Health Service Trust, Birmingham B9 5SS, United Kingdom; Translational Research Institute (M.R.), Hamad Medical Corporation, 3050 Doha, Qatar; Jining Medical University (J.C.), 273100 Jining, People's Republic of China; and Aston Medical Research Institute (I.K., H.S.R.), Aston Medical School, Aston University, Birmingham B4 7ET, United Kingdom.
Endocrinol Diabetes Metab Case Rep 2015 21;2015:150062. Epub 2015 Sep 21.
Warwick Institute for the Study of Endocrinology Diabetes and Metabolism (WISDEM Centre), The Arden NET Centre, University Hospitals of Coventry and Warwickshire, UHCW NHS Trust, ENETS CoE , Coventry , UK.
Anticancer Drugs 2014 Aug;25(7):841-7
aDepartment of Medicine, Second Division of Medical Oncology and Hematopoietic Cell Transplant Program bDepartment of Transfusion Medicine and Cell Processing Laboratory, 'Metaxa' Cancer Hospital, Piraeus, Greece.
Anticancer Drugs. 2014 Aug;25(7):841-7.
An appreciable percentage of patients with relapsed/refractory germ-cell tumors (GCTs), candidates for high-dose chemotherapy (HDC) and autologous hematopoietic cell transplantation (HCT), fail to mobilize adequate hematopoietic stem cells (HSCs) numbers with granulocyte colony-stimulating factor (G-CSF)±salvage chemotherapy. Plerixafor has shown a potential to mobilize adequate CD34+HSCs numbers in this context. Here, we applied plerixafor in combination with G-CSF after salvage chemotherapy in 'poor' mobilizers with relapsed/refractory GCTs for HDC+HCT. Patients with relapsed/refractory GCTs (n=10) received salvage paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy+G-CSF to mobilize adequate HSCs to support HDC, mainly with two courses of high-dose thiotepa-etoposide-carboplatin (TEC). Patients failing to achieve the minimum collection threshold of 2.0×10/kg CD34+ cells, to support at least one cycle of HDC, were administered plerixafor before the anticipated HSC collection during subsequent cycle(s). Overall, seven patients mobilized adequate CD34+ cells (>5.0×10/kg) aiming to support two cycles of HDC. Three patients did not mobilize adequate numbers of CD34+ cells after previous G-CSF plus salvage TIP, and plerixafor was added in subsequent cycle(s). This led to a collection of adequate CD34+ cells, able to support HDC with TEC (1-2 cycles). Hematopoietic engraftment for neutrophils (absolute neutrophil count>500/μl) and platelets (platelet count>20 000/μl) with plerixafor-mobilized HSCs occurred after a median of 9 and 14 days, respectively. Salvage TIP+G-CSF leads to successful HSC mobilization in patients with less heavily pretreated GCTs, whereas the addition of plerixafor to G-CSF+TIP led to mobilization of adequate HSCs that supported autografting after one to two TEC cycles.